Drug Profile
Research programme: adenosine A3 antagonists - Addex Pharmaceuticals
Alternative Names: Adenosine A3 orthosteric antagonists - AddexLatest Information Update: 14 Aug 2012
Price :
$50
*
At a glance
- Originator Addex Pharmaceuticals
- Developer Addex Therapeutics
- Class
- Mechanism of Action Adenosine A3 receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- Available For Licensing Yes - Glaucoma
Highest Development Phases
- Discontinued Glaucoma
Most Recent Events
- 16 Jul 2009 This adenosine A3 antagonist programme is available for licensing (http://addexpharma.com)
- 16 Jul 2009 Discontinued - Preclinical for Glaucoma in Switzerland (unspecified route)
- 29 Jan 2009 Preclinical trials in Glaucoma in Switzerland (unspecified route)